Comparative effectiveness and safety of apixaban and rivaroxaban in cirrhosis and atrial fibrillation

被引：0
|
作者：
Simon, Tracey G. [1 ]
Zhang, Yichi [2 ]
Mastrorilli, Julianna [3 ]
Cervone, Alexander [3 ]
Lin, Kueiyu Joshua [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
143
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [21] Using real-world data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK
    Gibbs, Liza
    Govil, Priya
    Kent, Seamus
    Duffield, Stephen
    Rowark, Shaun
    Sharma, Manuj
    Ali, Ayad
    Patrick, Amanda
    Jaksa, Ashley
    Jonsson, Pall
    Gatto, Nicolle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 74 - 74
  • [22] Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study
    Perreault, Sylvie
    Dragomir, Alice
    Cote, Robert
    Lenglet, Aurelie
    White-Guay, Brian
    de Denus, Simon
    Schnitzer, Mireille E.
    Dube, Marie-Pierre
    Brophy, James M.
    Dorais, Marc
    Tardif, Jean-Claude
    PHARMACOTHERAPY, 2021, 41 (04): : 379 - 393
  • [23] Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
    Grymonprez, Maxim
    De Backer, Tine L. L.
    Bertels, Xander
    Steurbaut, Stephane
    Lahousse, Lies
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [24] COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
    Garita, M.
    Peralta, M.
    Gordillo, D., I
    VALUE IN HEALTH, 2014, 17 (03) : A115 - A115
  • [25] Comparative Safety and Effectiveness of Apixaban Dosing in Patients With Atrial Fibrillation and Severe CKD
    Xu, Yunwen
    Chang, Alex R.
    Inker, Lesley A.
    McAdams-DeMarco, Mara
    Grams, Morgan
    Shin, Jung-Im
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 305 - 305
  • [26] Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study
    Fu, Edouard L.
    Desai, Rishi J.
    Paik, Julie M.
    Kim, Dae Hyun
    Zhang, Yichi
    Mastrorilli, Julianna M.
    Cervone, Alexander
    Lin, Kueiyu Joshua
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (03) : 293 - 305.e1
  • [27] Comparative effectiveness and safety of low versus high dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study
    Perreault, Sylvie
    Dragomir, Alice
    Cote, Robert
    White-Guay, Brian
    Lenglet, Aurelie
    Dorais, Marc
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 176 - 177
  • [28] Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation (vol 175, pg 1515, 2022)
    Lau, W. C. Y.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 144 - 144
  • [29] Apixaban vs rivaroxaban in patients with atrial fibrillation
    Reactions Weekly, 2020, 1796 (1) : 7 - 7
  • [30] Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation
    Norby, Faye L.
    Alonso, Alvaro
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (06) : 549 - 560
12345